BioNTech will provide an update on manufacturing and


MAINZ, Germany, June 9, 2022 (GLOBE NEWSWIRE)BioNTech SE (Nasdaq: BNTX, “BioNTech”) will welcome its African partners to the African continent for the first time and provide an update on joint establishment of mRNA manufacturing facilities and vaccine development plans. The event will include the inauguration of BioNTech’s first African mRNA manufacturing facility in Kigali, Rwanda, where the first BioNTainer modules are expected to be delivered by the end of 2022.

Following the invitation of HE President Paul Kagame of Rwanda, several Heads of State and Government are expected, as well as representatives at the highest level of the African Union, the European Union and the WHO. The event will take place on June 23, 2022, at approx. 11:30 a.m. CET / 5:30 a.m. ET. A limited number of accredited media representatives will be able to join the event on site. Interested journalists are invited to send a E-mail with the subject “BioNTainer in Africa“.

In February 2022, BioNTech presented its approach to establishing scalable vaccine production by developing and delivering turnkey mRNA manufacturing facilities based on a container solution called “BioNTainer”. BioNTech also plans to ship BioNTainers to Senegal and potentially South Africa in close coordination with the respective country and the African Union.

About BioNTech
Biopharmaceutical New Technologies is a next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company operates a wide range of computational discovery and therapeutic drug platforms for the rapid development of new biopharmaceuticals. Its broad pipeline of oncology product candidates includes individualized, ready-to-use mRNA therapies, innovative chimeric antigen receptor T cells, bispecific checkpoint immunomodulators, targeted cancer antibodies and small molecules. . Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing several mRNA vaccine candidates for a range of infectious diseases alongside its diverse pipeline in oncology. BioNTech has established a wide range of relationships with several global pharmaceutical collaborators, including Genmab, Sanofi, Genentech, member of the Roche Group, Regeneron, Genevant, Fosun Pharma and Pfizer. For more information, please visit


Investor Relations
Sylke Maas, Ph.D.
VP Investor Relations & Strategy
Tel: +49 (0)6131 9084 1074
E-mail: [email protected]

Media Relations
Jasmina Alatovic
VP Corporate Communications
Tel: +49 (0)6131 9084 1513 or +49 (0)151 1978 1385
E-mail: [email protected]


Comments are closed.